Home > Insider Trading > Filing (0001127602-15-004658)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1171694	C Frank Herringer	One Amgen Center Drive Thousand Oaks CA 91320-1799		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-02-05	5,000	$42.13	25,449	No	4	M	Direct
Common Stock	Disposition	2015-02-05	1,391	$151.45	24,058	No	4	F	Direct
Common Stock	Acquisiton	2015-02-05	1,500	$152.29	2,000	No	4	P	Indirect	The Julia Herringer 2012 Trust
Common Stock	Acquisiton	2015-02-05	1,500	$152.29	2,000	No	4	P	Indirect	The Sarah Herringer 2012 Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	F	Direct
No	4	P	Indirect	The Julia Herringer 2012 Trust
No	4	P	Indirect	The Sarah Herringer 2012 Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2015-02-05	5,000	$0.00	5,000	$42.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2008-04-29	2015-04-29	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,152	Indirect	Frank C & Maryellen C Herringer 1995 Family Trust
Common Stock	7,000	Indirect	Frank C. Herringer 1995 Family Trust

Footnotes

Non-market net exercise of 5,000 stock options expiring April 29, 2015 wherein 1,391 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price, with the remaining shares delivered to the reporting person. These shares include 881 Dividend Equivalent (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.